NO20084069L - N-formhylhydroksylamin-forbindelser - Google Patents

N-formhylhydroksylamin-forbindelser

Info

Publication number
NO20084069L
NO20084069L NO20084069A NO20084069A NO20084069L NO 20084069 L NO20084069 L NO 20084069L NO 20084069 A NO20084069 A NO 20084069A NO 20084069 A NO20084069 A NO 20084069A NO 20084069 L NO20084069 L NO 20084069L
Authority
NO
Norway
Prior art keywords
compounds
formhylhydroksylamin
formylhydroxylamine
peptidyl
formylase
Prior art date
Application number
NO20084069A
Other languages
English (en)
Inventor
Kwangho Lee
Jennifer Leeds
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084069L publication Critical patent/NO20084069L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nye N-formylhydroksylamin-forbindelser og deres derivater er beskrevet. Disse N-formylhydroksylamin-forbindelsene inhiberer peptidyldeformylase (PDF), et enzym til stede i prokaryoter. Forbindelsene er anvendelige som antimikrobielle midler og antibiotiske midler. Forbindelsene ifølge oppfinnelsen fremviser selektiv inhibering av peptidyldeformylase versus andre metalloproteinaser slike som MMP'er. Fremgangsmåter for fremstilling og anvendelse av forbindelsene er også beskrevet.
NO20084069A 2006-03-03 2008-09-24 N-formhylhydroksylamin-forbindelser NO20084069L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77937706P 2006-03-03 2006-03-03
PCT/US2007/063167 WO2007106670A2 (en) 2006-03-03 2007-03-02 N-formyl hydroxylamine compounds

Publications (1)

Publication Number Publication Date
NO20084069L true NO20084069L (no) 2008-12-03

Family

ID=38510154

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084069A NO20084069L (no) 2006-03-03 2008-09-24 N-formhylhydroksylamin-forbindelser

Country Status (19)

Country Link
US (1) US20090062537A1 (no)
EP (1) EP1994027A2 (no)
JP (1) JP2009529008A (no)
KR (1) KR20080095895A (no)
CN (1) CN101395148A (no)
AU (1) AU2007226715A1 (no)
BR (1) BRPI0708524A2 (no)
CA (1) CA2643267A1 (no)
CR (1) CR10251A (no)
EC (1) ECSP088712A (no)
GT (1) GT200800170A (no)
IL (1) IL193524A0 (no)
MA (1) MA30285B1 (no)
MX (1) MX2008011128A (no)
NO (1) NO20084069L (no)
RU (1) RU2008139192A (no)
TN (1) TNSN08344A1 (no)
WO (1) WO2007106670A2 (no)
ZA (1) ZA200807054B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
CN101869563B (zh) * 2010-07-02 2011-11-16 华东师范大学 含4-亚甲基吡咯烷的肽脱甲酰基酶抑制剂
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
CN103159660B (zh) * 2011-12-08 2016-07-06 天津市国际生物医药联合研究院 (2r)-1-(2-甲基-3-(甲氧基(甲基)氨基)-丙酰基)吡咯烷-2-羧酸及其应用
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
US9090559B2 (en) 2012-02-24 2015-07-28 Hoffmann-La Roche Inc. Antiviral compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
NZ723103A (en) * 2014-02-06 2022-09-30 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN108601764A (zh) 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
EP3526202A4 (en) 2016-10-11 2020-04-29 Arvinas, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
MX2019007646A (es) 2016-12-23 2019-09-06 Arvinas Operations Inc Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
JP7548992B2 (ja) 2019-07-17 2024-09-10 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
PE20221582A1 (es) 2019-12-19 2022-10-06 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos
US12043612B2 (en) 2020-05-09 2024-07-23 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
WO2022221673A1 (en) 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
AU2004216178B2 (en) * 2003-02-21 2008-07-03 Novartis Ag Chemical process for the preparation of intermediates to obtain N-formyl hydroxylamine compounds

Also Published As

Publication number Publication date
WO2007106670A3 (en) 2008-01-24
BRPI0708524A2 (pt) 2011-05-31
IL193524A0 (en) 2009-08-03
ECSP088712A (es) 2008-10-31
TNSN08344A1 (en) 2009-12-29
ZA200807054B (en) 2009-10-28
KR20080095895A (ko) 2008-10-29
WO2007106670A2 (en) 2007-09-20
MA30285B1 (fr) 2009-03-02
US20090062537A1 (en) 2009-03-05
CA2643267A1 (en) 2007-09-20
JP2009529008A (ja) 2009-08-13
AU2007226715A1 (en) 2007-09-20
CR10251A (es) 2008-10-27
EP1994027A2 (en) 2008-11-26
GT200800170A (es) 2008-10-29
CN101395148A (zh) 2009-03-25
MX2008011128A (es) 2008-09-08
RU2008139192A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
NO20084069L (no) N-formhylhydroksylamin-forbindelser
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
NO20090628L (no) Pyridizinon derivativater
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20071593L (no) Pyrimidinderivater
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
BRPI0608886B8 (pt) derivados de n-sulfonilpirróis e seus usos
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
DK1899325T3 (da) Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
WO2007077186A8 (en) Pdf inhibitors
TW200706534A (en) N-formyl hydroxylamine compounds
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
NO20050346L (no) Nitro-oksyderivater av syklooksygenase-2-inhibitorer
ATE509920T1 (de) Quadratsäurederivate als inhibitoren von histondeacetylase
NO20025811L (no) Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
NO20076694L (no) Sulfonamidforbindelser og anvendelser derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application